Demonstration that donor-specific nonresponsiveness in human liver allograft recipients is both rare and transient

Transplantation

Volumn 77, Issue 8, 2004, Pages 1246-1252

  Hathaway, Mark ^a   Adams, David H ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

ALLOGRAFT; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HLA MATCHING; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 2342507669     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000121136.84965.35     Document Type: Article

References (26)

1. Freese DK, Snover DC, Sharp HL, et al. Chronic rejection after liver transplantation: A study of clinical, histopathological and immunological features. Hepatology 1991; 13: 882.
2. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926.
3. Jamil B, Nicholls K, Becker GJ, et al. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999; 68: 1597.
4. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998: 147.
5. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: The problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001; 71: SS42.
6. Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Ann Transplant 2001; 6: 25.
7. Calne RY, White HJ, Binns RM, et al. Immunosuppressive effects of the orthotopically transplanted porcine liver. Transplant Proc 1969; 1: 321.
8. Qian S, Demetris AJ, Murase N, et al. Murine liver allograft transplantation: Tolerance and donor cell chimerism. Hepatology 1994; 19: 916.
9. Kamada N, Brons G, Davies HS. Fully allogeneic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens. Transplantation 1980; 29: 429.
10. Wong T, Nouri-Aria KT, Devlin J, et al. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998; 28: 443.
11. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243.
12. Sandborn WJ, Hay JE, Porayko MK, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19: 925.
13. Golling M, Frankenberg MV, Hofmann WJ, et al. Cyclosporine A reduction and withdrawal in liver transplantation: A risk-benefit analysis. Transplant Proc 1997; 29: 2819.
14. Hornick PI, Brookes PA, Mason PD, et al. Optimizing a limiting dilution culture system for quantifying the frequency of interleukin-2-producing alloreactive T helper lymphocytes. Transplantation 1997; 64: 472.
15. de Haan A, van den Berg AP, Hepkema BG, et al. Donor-specific hyporeactivity after liver transplantation: Prominent decreases in donor-specific cytotoxic T lymphocyte precursor frequencies independent of changes in helper T lymphocyte precursor frequencies or suppressor cell activity. Transplantation 1998; 66: 516.
16. Mathew JM, Marsh JW, Susskind B, et al. Analysis of T cell responses in liver allograft recipients: Evidence for deletion of donor-specific cytotoxic T cells in the peripheral circulation. J Clin Invest 1993; 91: 900.
17. van Twuyver E, de Hoop J, ten Berge RJ, et al. Comparison of T cell responses in patients with a long-term surviving renal allograft versus a long-term surviving liver allograft: It's a different world. Transplantation 1996; 61: 1392.
18. Schulick RD, Weir MB, Miller MW, et al. Longitudinal study of in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs. Transplantation 1993; 56: 590.
19. Boyum A. Separation of blood leucocytes, granulocytes and lymphocytes. Tissue Antigens 1974; 4: 269.
20. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999; 45: 1477.
21. van den Berg AP, Twilhaar WN, Mesander G, et al. Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation 1998; 65: 1066.
22. Creemers P, Du TE, Cassidy MJ, et al. Sequential mixed lymphocyte culture after kidney transplantation: Induction of tolerance or sensitization. Nephron 1997; 75: 166.
23. Goulmy E, Stijnen T, Groenewoud AF, et al. Renal transplant patients monitored by the cell-mediated lympholysis assay: Evaluation of its clinical value. Transplantation 1989; 48: 559.
24. van Besouw NM, van der Mast BJ, de Kuiper P, et al. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 2000; 70: 136.
25. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145.
26. Geissler F, Jankowska-Gan E, DeVito-Haynes LD, et al. Human liver allograft acceptance and the "tolerance assay": In vitro anti-donor T cell assays show hyporeactivity to donor cells, but unlike DTH, fail to detect linked suppression. Transplantation 2001; 72: 571.